CLINICAL ROLE -
Sotorasib Plus Panitumumab Significantly Improves Outcomes in Colorectal Cancer
Combination treatment of sotorasib plus panitumumab prolongs progression-free survival in those with metastatic colorectal cancer and the KRAS G12C mutation.
Read More
Enfortumab Vedotin With Pembrolizumab Shows Promise as First-Line Therapy For Those Ineligible for Cisplatin
Enfortumab vedotin in combination with pembrolizumab showed a manageable safety profile and promising progression free survival and overall survival for locally advanced or metastatic urothelial cancer.